Aktienanalyse zu Aprea Therapeutics Inc (APRE)APREAprea Therapeutics Inc

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aprea Therapeutics Inc is a good buy right now due to its recent price increase of 8.96% over the last five days, indicating positive momentum. The stock's current price is $0.53, which is significantly below its 52-week high of $1.49, suggesting potential for upside. Additionally, the company has a strong cash position of $46.5 million as of March 31, 2026, which is expected to sustain operations until Q1 2028, reducing financial risk. However, the main risk is the ongoing negative earnings trend, with a reported EPS of -0.09 in the last quarter, which reflects continued losses.